Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs IV Antiemetics for Breast Cancer CINV
NCT05841849Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of palonosetron, aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
palonosetronaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05841849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841849.